The University of Pittsburgh Cancer Institute (UPCI) will host the second Invasive Lobular Carcinoma (ILC) International Symposium. Clinical experts will explore ILC, the second most common type of breast cancer and the eighth most common cancer in women. The goal is to begin the process of leading research that will ultimately result in improved outcomes for patients with this disease.
ILC is often difficult to diagnose since it typically does not cause a firm or distinct breast lump. Clinical and laboratory studies of breast cancer have focused almost exclusively on the more common invasive ductal cancers (IDC). Prior to the first ILC symposium held in 2016, there has never been a focused meeting to discuss basic, translational and clinical research on ILC, which affects nearly 30,000 women each year.
The target audience for this symposium is researchers interested in lobular cancer, as well as medical, surgical, and radiation oncologists interested in the treatment of patients with invasive lobular carcinoma in situ (LCIS) or ILC. Patient advocate breakout sessions and networking opportunities will be included in the program. Patient advocates for lobular cancer and other healthcare professionals are encouraged to attend.